IDT Biologika is a leading biologics CDMO providing development and manufacturing of Vaccines, Viral Vectors for Cell & Gene Therapeutics, Oncolytic Viruses, Virus-Like Particles, and aseptic fill-finish for other Biologics, with end-to-end capabilities serving companies worldwide.
Our North American CDMO site is a GMP-compliant facility (BSL-2) with a long history of contract manufacturing of clinical trial materials. It shares many of the state-of-the-art technologies used at our German facility that has both clinical and commercial capacity.
Year Founded 1921
1,850
employees in 2022
3 BSL-2 Sites
Worldwide Services for the global biopharmaceutical industry and governments
Over 30 years of experience in commercial filling of pharmaceuticals
More than 200 development, clinical and commercial projects in recent years
Over € 600 m
invested since 1993, including € 400 m since 2011
More than a century of experience in development and production of vaccines
Approvals
EMA, FDA, ANVISA
First German company which has its pandemic readiness confirmed by the German government.
December 7, 2023
2 PM CET, Location: MassBioHub, 700 Technology Sq., Cambridge, MA 02139
If you want to further your career with a global leader in vaccines, cell and gene therapeutics, and other biologics CDMO services, visit IDT Biologika’s careers section for opportunities in Europe and North America.
Let us help you with your project. To ensure, we have the information we need, please fill out the form.